FDA Inspection 1006385 — Quintiles Beograd D.O.O
The FDA completed an inspection of Quintiles Beograd D.O.O on Mar 2, 2017 in Belgrade. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 2, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Belgrade (Serbia)
Additional details
Sponsor, Contract Research Organization